BioLife Solutions, Inc.
BLFS
$35.07
-$0.16-0.45%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 32.69% | 32.58% | 31.72% | 66.04% | 47.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.69% | 32.58% | 31.72% | 66.04% | 47.51% |
| Cost of Revenue | 44.93% | 46.80% | 41.95% | 497.14% | 196.47% |
| Gross Profit | 26.58% | 25.66% | 26.70% | 21.18% | 17.92% |
| SG&A Expenses | 7.01% | 11.92% | 12.33% | 31.55% | 14.48% |
| Depreciation & Amortization | 203.18% | 355.15% | 241.06% | -166.71% | -147.20% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.25% | 30.73% | 25.87% | 59.92% | 25.03% |
| Operating Income | 258.57% | 55.56% | 71.57% | 73.42% | 90.91% |
| Income Before Tax | 144.28% | -111.15% | -39.09% | -763.35% | -14.73% |
| Income Tax Expenses | -50,552.38% | 336.59% | 228.95% | 183.39% | 184.00% |
| Earnings from Continuing Operations | 425.15% | -114.60% | -40.25% | -691.04% | -16.26% |
| Earnings from Discontinued Operations | -6.13% | 265.70% | 167.77% | 121.57% | 115.38% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,148.46% | 71.55% | 77.23% | 93.26% | 92.63% |
| EBIT | 258.57% | 55.56% | 71.57% | 73.42% | 90.91% |
| EBITDA | 22.04% | -53.86% | -59.61% | -50.22% | 808.85% |
| EPS Basic | 1,175.34% | 72.14% | 77.99% | 94.19% | 93.40% |
| Normalized Basic EPS | 1,427.27% | 379.47% | 162.88% | 163.98% | 103.53% |
| EPS Diluted | 1,077.96% | 66.96% | 76.16% | 93.12% | 92.91% |
| Normalized Diluted EPS | 1,494.23% | 370.98% | 161.62% | 162.54% | 103.34% |
| Average Basic Shares Outstanding | 3.00% | 3.42% | 3.66% | 3.88% | 4.41% |
| Average Diluted Shares Outstanding | 3.10% | 3.29% | 4.45% | 5.75% | 5.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |